Image may be NSFW.
Clik here to view.
Reblogged from :
On December 20, GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV), announce that the FDA grants a Breakthrough Therapy Designation (BTD) for Tafenoquine, an investigational medicine for the treatment and relapse prevention of Plasmodium vivax malaria. This is the 28th BTD that is announced by a sponsor company – GSK and MMV. This is the 3rd FDA BTD that GSK receives in 2013:
